Whitehawk Therapeutics, Inc. - 10-Q Filing

Whitehawk Therapeutics reports Q3 2025 financial results including restructuring plan activity and ongoing R&D expenses.

SEC EDGAR ·

Tickers: $WHWK

Read the full article at SEC EDGAR

More Regulatory news